Eli Lilly and Co
LLYToday
+0.86%
5 Days
-1.58%
1 Month
+4.37%
6 Months
+3.26%
Year to Date
+3.43%
1 Year
+45.73%
TradingKey Stock Score of Eli Lilly and Co
Currency: USD Updated: 2026-06-22Key Insights
Eli Lilly and Co's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 20 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 1210.97.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Eli Lilly and Co's Score
Support & Resistance
Score Analysis
Media Coverage
Eli Lilly and Co Highlights
Eli Lilly and Company, commonly referred to as Lilly, is an American multinational pharmaceutical corporation based in Indianapolis, Indiana, with offices in 18 countries and products available in approximately 125 nations. Founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran from the American Civil War, the company carries his name.
As of October 2024, Lilly has achieved the status of the most valuable drug company in the world, boasting a market capitalization of $842 billion, marking the highest valuation ever recorded for a pharmaceutical company. The firm ranks 127th on the Fortune 500, reporting revenues of $34.12 billion. Additionally, it is positioned 221st on the Forbes Global 2000 list, which encompasses the largest publicly traded companies globally, and 252nd on Forbes' list of "America's Best Employers."
Lilly is recognized for its antidepressant medications, including Prozac and Cymbalta, as well as the antipsychotic drug Zyprexa. Its primary revenue sources are the diabetes treatments Humalog and Trulicity.
The company was a pioneer in mass-producing both the polio vaccine, created in 1955 by Jonas Salk, and insulin. Lilly was among the first in the pharmaceutical sector to manufacture human insulin using recombinant DNA technology, producing products like Humulin, Humalog, and the first approved biosimilar insulin in the U.S., known as Basaglar. Additionally, Lilly introduced exenatide to the market as the first of the GLP-1 receptor agonists, followed by highly successful medications in this category, such as Mounjaro and Zepbound.
By 1997, Lilly had become both the largest corporation and the largest philanthropic benefactor in Indiana. In 2009, it pleaded guilty to illegally marketing Zyprexa and agreed to a substantial $1.415 billion settlement, which included a criminal fine of $515 million, making it the largest ever in a healthcare-related case and the highest criminal fine levied against a single corporation in a U.S. criminal prosecution at that time.
Lilly is a full member of the Pharmaceutical Research and Manufacturers of America, as well as the European Federation of Pharmaceutical Industries and Associations.
Analyst Rating
Eli Lilly and Co News
US Pre-Market: Chip Stocks Rebound Leads Nasdaq Futures, Marvell Surges Nearly 9% Pre-Market to Be Added to S&P 500
TradingKey - On Monday Eastern Time, all three major U.S. stock index futures rose in pre-market trading as technology stocks recovered from last week's sell-off, with a rebound in chip stocks leading gains in Nasdaq futures. However, escalating tensions in the Middle East pushed oil prices higher, and market concerns regarding inflationary pressures and the Federal Reserve's policy path persist. As of press time, Dow futures rose 0.36%, S&P 500 futures rose 0.83%, and Nasdaq futures rose 1.49%.
Eli Lilly Zepbound Returns to CVS Formulary, Pre-Market Shares Rise as Much as 2%
TradingKey - Eli Lilly (LLY) shares rose nearly 2% in Thursday’s pre-market session as the market focused on a major decision from U.S. healthcare giant CVS Health (CVS). CVS announced it would restore insurance coverage for the weight-loss drug Zepbound and include Foundayo, an oral weight-loss medication newly approved in April, in its standard drug formulary.
Eli Lilly Bets Nearly $4 Billion on Vaccines: Is the Weight-Loss Drug Giant’s Next Growth Curve Here?
TradingKey - On May 26, Eli Lilly (LLY) announced the acquisition of three vaccine R&D companies—Curevo, LimmaTech Biologics, and Vaccine Company—for a total transaction value of up to nearly $4 billion. Specifically, Eli Lilly will pay up to $1.5 billion in cash for Curevo, up to $780 million for LimmaTech, and up to $1.55 billion for Vaccine Company.
Today’s Market Recap:Optimism over US-Iran Talks Drives US Stock Futures Higher, Crude Oil Plunges 6%
TradingKey - Stock futures jumped on Monday night as oil prices slid and hope grew that a resolution to the U.S.-Iran war was within reach.
Eli Lilly Weight-Loss Drug Retatrutide Posts Impressive Data; Can Novo Nordisk Break Through After Falling Behind Again?
TradingKey - On May 21, Eastern Time, Eli Lilly announced the results of the pivotal Phase 3 clinical trial (TRIUMPH-1) for its next-generation weight-loss drug, Retatrutide. As the world's first "triple agonist" targeting GIP, GLP-1, and glucagon receptors, its efficacy data has comprehensively sur
Hold or Diversify? Why This Forgotten Industry Deserves a Look
Recent market performance has been more than just strong
Financial Indicators
EPS
Total revenue
Eli Lilly and Co Info
Eli Lilly and Company, commonly referred to as Lilly, is an American multinational pharmaceutical corporation based in Indianapolis, Indiana, with offices in 18 countries and products available in approximately 125 nations. Founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran from the American Civil War, the company carries his name.
As of October 2024, Lilly has achieved the status of the most valuable drug company in the world, boasting a market capitalization of $842 billion, marking the highest valuation ever recorded for a pharmaceutical company. The firm ranks 127th on the Fortune 500, reporting revenues of $34.12 billion. Additionally, it is positioned 221st on the Forbes Global 2000 list, which encompasses the largest publicly traded companies globally, and 252nd on Forbes' list of "America's Best Employers."
Lilly is recognized for its antidepressant medications, including Prozac and Cymbalta, as well as the antipsychotic drug Zyprexa. Its primary revenue sources are the diabetes treatments Humalog and Trulicity.
The company was a pioneer in mass-producing both the polio vaccine, created in 1955 by Jonas Salk, and insulin. Lilly was among the first in the pharmaceutical sector to manufacture human insulin using recombinant DNA technology, producing products like Humulin, Humalog, and the first approved biosimilar insulin in the U.S., known as Basaglar. Additionally, Lilly introduced exenatide to the market as the first of the GLP-1 receptor agonists, followed by highly successful medications in this category, such as Mounjaro and Zepbound.
By 1997, Lilly had become both the largest corporation and the largest philanthropic benefactor in Indiana. In 2009, it pleaded guilty to illegally marketing Zyprexa and agreed to a substantial $1.415 billion settlement, which included a criminal fine of $515 million, making it the largest ever in a healthcare-related case and the highest criminal fine levied against a single corporation in a U.S. criminal prosecution at that time.
Lilly is a full member of the Pharmaceutical Research and Manufacturers of America, as well as the European Federation of Pharmaceutical Industries and Associations.
Related Instruments
Popular Instruments
